Abstract
Conflict of interest
WH Boehncke has received honoraria as an advisor from the following companies: AbbVie, Almirall, BMS, Celgene, Leo, Lilly, Novartis and UCB. WHB has received honoraria as a speaker on the occasion of sponsored symposia from AbbVie, Almirall, Celgene, Leo and Novartis. WHB has received a research grant from Pfizer. AGA Kolios has served as an investigator, speaker and/or advisor for AbbVie, Abbott, Amgen, Celgene, Janssen, Eli Lilly, Leo, MSD, Novartis and Pfizer and does not hold any shares or other financial interest in any related pharmaceutical company. C Mainetti has received honoraria for Advisory Boards from LEO Pharma, AbbVie, Almirall, Celgene and Eli Lilly. K Heidemeyer received honoraria for consulting and advisory board attendance from AbbVie, Celgene, Eli Lilly, Galderma and Novartis. N Yawalkar has received honoraria for consulting and advisory board attendance from AbbVie, Almirall, Amgen, Celgene, Eli Lilly, Galderma, Janssen, Leo, Novartis, MSD and Pfizer. S Cazzaniga, F Anzengruber, M Augustin, L Borradori, C Conrad, A Cozzio, V Djamei, LE French, M Gilliet, P Häusermann, P Itin, E Laffitte, J‐T Maul, L Naldi, AA Navarini, SJ Rustenbach, D Simon, C Sorbe and M Streit have no conflict of interest to declare.
Funding source
The registry was supported by AbbVie, Celgene, Janssen, Lilly, Novartis and Pfizer. These companies do not have any influence on design of the register, data collection and analyses as well as on publication decisions or manuscript constructions.
Cazzaniga, S